Oncology
EGFR
CHEMBL203
5,497 ADMET-validated compounds across 35,946 generated. Library buildup phase — Pareto rank-1 selection underway prior to CRO triage.
ADMET Passed
5,497
Pareto Rank-1 Count
447
CRO
Accumulating
Stage
Library buildup
Pareto Rank-1 is a front-membership count, not a quality ranking — the front is near-saturated, so it does not discriminate quality. Meaningful selection uses consensus + wet-lab.
Mechanism
EGFR (HER1) tyrosine kinase inhibition — RTK signaling node for cell proliferation and survival
Precedent
Erlotinib, Gefitinib (1st-gen, 2003–2004) · Afatinib (2nd-gen) · Osimertinib (AstraZeneca, 3rd-gen, approved 2015) · Lazertinib (Yuhan/J&J)
Indications
NSCLC · Glioblastoma · Pancreatic cancer
Milestones
2026-W17
EGFR added as 5th target — pipeline integration complete
2026-W18
ADMET library passing 5,000 compounds — Pareto convergence beginning